Nxera Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Nxera Pharma kazanç ve gelirin sırasıyla yıllık 47.3% ve 9.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 52.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 6.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

47.3%

Kazanç büyüme oranı

52.2%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.9%
Gelir büyüme oranı	9.3%
Gelecekteki özkaynak getirisi	6.1%
Analist kapsamı	Good
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:SOLT.F - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	43,289	2,285	4,652	5,130	9
12/31/2025	39,632	3,472	5,079	4,583	10
12/31/2024	34,676	1,031	2,809	3,050	8
9/30/2024	29,275	-3,711	1,705	2,425	N/A
6/30/2024	23,340	-9,836	-1,526	-782	N/A
3/31/2024	16,434	-9,072	-7,091	-6,321	N/A
12/31/2023	12,766	-7,193	-6,124	-5,273	N/A
9/30/2023	12,402	-3,378	38	653	N/A
6/30/2023	15,258	1,860	9,821	10,153	N/A
3/31/2023	15,393	1,050	10,043	10,386	N/A
12/31/2022	15,569	382	9,649	9,952	N/A
9/30/2022	22,763	-383	14,534	14,836	N/A
6/30/2022	17,046	-224	5,074	5,389	N/A
3/31/2022	17,624	100	6,165	6,394	N/A
12/31/2021	17,712	1,017	6,894	7,095	N/A
9/30/2021	7,989	1,296	-589	-448	N/A
6/30/2021	9,449	1,299	2,013	2,140	N/A
3/31/2021	8,887	1,072	2,186	2,313	N/A
12/31/2020	8,842	1,479	4,567	4,672	N/A
9/30/2020	6,399	-1,671	1,352	1,441	N/A
6/30/2020	7,186	-1,080	4,315	4,422	N/A
3/31/2020	7,752	-332	4,362	4,551	N/A
12/31/2019	9,726	1,432	3,161	3,441	N/A
12/31/2018	3,550	-6,918	-8,648	-6,047	N/A
9/30/2018	3,444	-5,483	-7,726	-5,640	N/A
6/30/2018	5,005	-4,202	N/A	-3,358	N/A
3/31/2018	6,955	-2,654	N/A	-2,167	N/A
12/31/2017	8,060	-2,608	N/A	609	N/A
9/30/2017	8,376	-1,338	N/A	211	N/A
6/30/2017	6,603	-1,547	N/A	-1,102	N/A
3/31/2017	18,901	9,311	N/A	12,856	N/A
12/31/2016	17,528	6,481	N/A	11,424	N/A
9/30/2016	21,450	9,514	N/A	15,378	N/A
6/30/2016	22,658	10,508	N/A	17,064	N/A
3/31/2016	8,151	-1,432	N/A	4,471	N/A
12/31/2015	10,461	2,599	N/A	4,928	N/A
9/30/2015	5,646	-255	N/A	1,503	N/A
6/30/2015	4,010	-118	N/A	929	N/A
3/31/2015	3,671	568	N/A	92	N/A
12/31/2014	1,169	2,191	N/A	N/A	N/A
9/30/2014	1,051	1,593	N/A	1,079	N/A
6/30/2014	2,236	2,030	N/A	N/A	N/A
3/31/2014	2,069	1,526	N/A	363	N/A
12/31/2013	1,948	-849	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SOLT.F önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: SOLT.F önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: SOLT.F önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: SOLT.F şirketinin gelirinin (yıllık 9.3% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SOLT.F şirketinin gelirinin (yıllık 9.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SOLT.F 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 6.1 %).

Nxera Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease

Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea

Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024

Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant

Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023

Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences

Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Sosei Group Corporation Provides Update of Their Strategic Multi-Target Drug Discovery Collaboration with Pfizer

Sosei Group Corporation to Report Q1, 2021 Results on May 12, 2021

Sosei Group Corporation, Annual General Meeting, Mar 24, 2021

Sosei Heptares to Explore Structure-Based Drug Discovery (SBDD) Approaches to Ion Channels Through Strategic Technology Collaboration with Metrion Biosciences

Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-Driven Drug Discovery Against Challenging GPCR Target

Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs

Sosei Group Corporation's Brand Sosei Heptares and Captor Therapeutics SA Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

Sosei Group Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021

Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

Sosei Group Corporation Announces Progress Update for Its R&D Program Focused on the Design and Development of Novel Drugs Targeting the SARS-CoV-2 Coronavirus and to Treat COVID-19

Sosei Heptares Announces a Second Novel Drug Candidate from its Multi-Target Drug Discovery Collaboration with Pfizer Starts Clinical Trials

Sosei Group Corporation to Report Q3, 2020 Results on Nov 11, 2020

Sosei Group Corporation has completed a Follow-on Equity Offering in the amount of ¥5.265733 billion.

Sosei Group Corporation to Report Q2, 2020 Results on Aug 13, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin